CN105693817B - 一类三肽化合物及其制备方法与应用 - Google Patents
一类三肽化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN105693817B CN105693817B CN201410705180.3A CN201410705180A CN105693817B CN 105693817 B CN105693817 B CN 105693817B CN 201410705180 A CN201410705180 A CN 201410705180A CN 105693817 B CN105693817 B CN 105693817B
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- myocardial
- hypertension
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 206010020772 Hypertension Diseases 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 22
- 201000009925 nephrosclerosis Diseases 0.000 claims description 10
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
- 206010020571 Hyperaldosteronism Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 5
- 238000007634 remodeling Methods 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004220 fundus oculi Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract description 32
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract description 32
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000004071 biological effect Effects 0.000 abstract description 4
- -1 sulfinylamino Chemical group 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 238000000034 method Methods 0.000 description 40
- 125000000217 alkyl group Chemical group 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 241000700159 Rattus Species 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- 125000000753 cycloalkyl group Chemical group 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 17
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 125000003710 aryl alkyl group Chemical group 0.000 description 15
- 229940093499 ethyl acetate Drugs 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 230000036772 blood pressure Effects 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000004414 alkyl thio group Chemical group 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 125000004475 heteroaralkyl group Chemical group 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 230000004873 systolic arterial blood pressure Effects 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229960000830 captopril Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001475 halogen functional group Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229910052717 sulfur Chemical group 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 150000001447 alkali salts Chemical class 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- 229940098895 maleic acid Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N tetramethyl-pyrazine Natural products CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 229930194268 Salvianic acid Natural products 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 125000003435 aroyl group Chemical group 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IAJBQAYHSQIQRE-UHFFFAOYSA-N 2,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(OC)=C(C=O)C=C1OC IAJBQAYHSQIQRE-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 101000773741 Mus musculus Angiotensin-converting enzyme Proteins 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- DNAVOCNYHNNEQI-UHFFFAOYSA-N asaronaldehyde Natural products COC1=CC(OC)=C(C=CC=O)C=C1OC DNAVOCNYHNNEQI-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- JXGVXCZADZNAMJ-NSHDSACASA-N (2s)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-NSHDSACASA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical group 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 description 1
- 125000005281 alkyl ureido group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- YQCIWBXEVYWRCW-UHFFFAOYSA-N methane;sulfane Chemical compound C.S YQCIWBXEVYWRCW-UHFFFAOYSA-N 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- MHZDONKZSXBOGL-UHFFFAOYSA-N propyl dihydrogen phosphate Chemical compound CCCOP(O)(O)=O MHZDONKZSXBOGL-UHFFFAOYSA-N 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- 108700035424 spirapril Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical group C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- OHSJPLSEQNCRLW-UHFFFAOYSA-N triphenylmethyl radical Chemical compound C1=CC=CC=C1[C](C=1C=CC=CC=1)C1=CC=CC=C1 OHSJPLSEQNCRLW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
本发明涉及一类三肽化合物及其制备方法与应用。所涉及的化合物结构通式如式(I)所示。本发明的化合物具有抑制血管紧张素转化酶的生物活性,其本身及其药物组合物对高血压以及其他心脑血管系统疾病的预防与治疗方面的作用。
Description
技术领域
本发明涉及一类新的化合物式(I)及相应的药学上可以接受的盐。本发明还涉及该类化合物或其相应盐或其中间体的制备方法。本发明还涉及到所述化合物的药物组合物。这些化合物具有抑制血管紧张素转化酶的生物活性,其本身及其药物组合物对高血压以及其他心脑血管系统疾病的预防与治疗方面的作用。
背景技术
2013年世界卫生日的主题就是控制高血压。据世界卫生组织(WHO)公布的调查数据可知,高血压及其相关并发症疾病已成为威胁人类生命健康的主要疾病之一,其发病率和死亡率已超过肿瘤性疾病跃居第一。世界范围内约有10亿高血压患者,每年导致710万例心血管死亡,如不控制,2025年其患病人数将增至15.6亿。中国疾病预防控制中心慢性非传染疾病预防控制中心最新的研究结果公布——2010年中国成年人中高血压患病率高达33.5%,据此估计患病总人数已突破3.3亿。高血压是心脏病、脑卒中、肾脏病和糖尿病发病和死亡的最大的危险因素,每年200万人死亡与高血压有关,高血压已成为重要公共卫生问题。(2012年10月10日16:26来源:中国新闻网)高血压疾病及其并发症给社会和家庭带来了巨大的疫病经济负担。迄今为止,人们对于高血压及其并发症的治疗研究已取得了巨大进展,但是仍然无法完全解决高血压患者的痛苦。与此同时,高血压及其并发症的广泛危害性引起了抗高血压药物市场的快速发展。近30年以来,高血压治疗以药物为主,并逐渐形成了包含利尿剂、β-受体阻滞剂、α-受体阻滞剂、钙拮抗剂(CCB)、血管紧张素转换酶抑制剂(ACEI)、血管紧张素受体拮抗剂(ARB)在内的六大类降压药物及其不同组合。
其中,血管紧张素转换酶抑制剂(angiotension converting enzymeinhibition,ACEI),自1981年卡托普利问世以来,以脯氨酸为母核针对血管紧张素转换酶(angiotension converting enzyme,ACE,是一种含有锌离子的外肽酶)为靶点的药物设计一直是降压领域的研究热点,并成功设计出二肽、三肽等含有巯基、羧酸、磷酸等关键官能团的ACEI药物及前导化合物。到目前为止,已有至少17种ACEI类药物成为临床上治疗高血压的一线药物。其他降压药也各有不同的侧重,特别是ARB类降压药以其缓和长效、低副作用逐渐成为降压药的重要组成部分。然而,临床病例中,高血压患者常伴有糖尿病、肾脏病等其他心脑血管疾病。仅用一种降压药往往不能达到较好的疗效,故两种或多种降压药联合应用已经成为临床降压用药的趋势。因此,开发多效、多适应症、更为优效的降压药物势在必行。
发明内容
本发明提供了一类三肽化合物,该化合物结构通式(I)如下:
通式(I)中:
R为通式(II)所示:
通式(II)中:
R1选自氢、烷基、环烷基、杂烷基、杂环基、烯基、炔基、酰基、芳酰基、芳基、芳烷基、杂芳基或杂芳烷基;
R2选自氢、烷基、环烷基、杂烷基、杂环基、烯基、炔基、酰基、芳酰基、芳基、芳烷基、杂芳基、杂芳烷基、烷硫基、芳烷硫基、芳硫基、F、Cl、Br、I、NO2或CN;
R1和R2相同或不同;
n=0,1,2,3,4,5;n≥2时,多个R1之间相同或不同;
m=0,1,2,3,4,5;m≥2时,多个R2之间相同或不同;
X选自氧或氢;
通式(I)中:
R′为L型或D型氨基酸残基或氨基酸衍生物的残基,如通式(III)所示,或者,R′不存在:
R4与R5各自独立选自氢、烷基、环烷基、杂烷基、杂环基、烯基、炔基、芳基、芳烷基、杂芳基和杂芳烷基;R4与R5相同或不同;
通式(I)中:
R″为通式(IV)所示:
其中:
Y选自氧、氮或硫,并且:
Y为氧时,R″″为R9,R″为-OR9;
Y为硫时,R″″为R10,R″为-SR10;
其中:R7、R8、R9、R10可以相同或不同,各自独立选自氢、烷基、环烷基、杂烷基、杂环基、烯基、炔基、芳基、芳烷基、杂芳基或杂芳烷基;
通式(I)中:
R″′选自氢或烷基;
A=碳;
L选自氢、烷基、取代烷基、芳基或取代芳基;
D为碳或不存在,t=0,1,2,3;并且:
当D为碳,B为碳时:A与B之间为碳碳双键或碳碳单键,K与B、D之间为环系关系;或者,A与B之间为碳碳双键或碳碳单键,K与B连接且K与D不相连;
当K与B、D之间为环系关系时,K选自碳数为2到8烷基、杂烷基、碳数为3到8烯基,或者,K与B、D之间共同形成芳基、取代芳基、杂芳基或取代杂芳基;
当K与B连接且K与D不相连时,K选自氢、烷基、杂烷基、环烷基、杂环基、烯基、炔基、羟基、烷氧基、芳氧基、芳基、芳烷基、杂芳基或杂芳烷基;
当D为碳,B为硫时:则A与B之间为碳硫单键,K不存在;
当D不存时:B为碳,K为氢;
所述烷基、环烷基、杂烷基、杂环基、烯基、炔基、芳基、芳烷基、杂芳基和杂芳烷基各自可为未取代或任选独立的被一或多个选自以以下部分的取代基:羟基、烷氧基、芳氧基、硫代、硫代烷基、芳硫基、氨基、酰胺基、烷氨基、芳氨基、烷基磺酰基、芳基磺酰基、亚磺酰基氨基、烷基、芳基、杂芳基、烷基亚磺酰胺基、芳基亚磺酰胺基、酮基、羧基、烷氧羰基、羧酰胺基、烷氧羰基氨基、烷氧羰基氧基、烷基脲基、芳基脲基、卤代、氰基或硝基。
可选的,所述R基团
选自下列结构:
可选的,所述R′基团
选自下列结构:
其中,“*”代表手性中心,含有“*”的所述化合物包含该结构式的所有手性构型同分异构体。
可选的,当Y为氧时,R9为选自下列的基团:
甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、环丙基、环丁基、环戊基、环己基、环庚基或下列结构:
可选的,当Y为氮时,R″为选自下列的基团:
其中,“*”代表手性中心,含有“*”的所述化合物包含该结构式的所有手性构型同分异构体。
可选的,当Y为硫时,R″为选自下列的基团:
其中,“*”代表手性中心,含有“*”的所述化合物包含该结构式的所有手性构型同分异构体。
可选的,上述通式(I)选自下列通式结构:
其中,“*”代表手性中心,含有“*”的所述化合物包含该结构式的所有手性构型同分异构体。
可选的,上述的三肽化合物选自下列结构的化合物:
其中,“*”代表手性中心,含有“*”的所述化合物包含该结构式的所有手性构型同分异构体。
本发明还提供了上述化合物中Y为氧时的化合物的水解产物。
本发明同时还提供了上述化合物的对映体、互变异构体、立体异构体、旋转异构体、非对映异构体或外消旋体。
本发明同时又提供了上述化合物药学上可接受的盐和药学上可接受的酯,所述药学上可接受的盐包括药学上可接受的酸式盐和药学上可接受的碱式盐,所述药学上可以接受的酸式盐包括下列酸中其中之一所形成的盐:硫酸、硫酸氢、盐酸、氢溴酸、磷酸、硝酸、碳酸、硼酸、甲磺酸、苯磺酸、对甲基苯磺酸、甲酸、乙酸、丙酸、丁酸、丙酮酸、马来酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、苯甲酸、樟脑酸、富马酸、草酸、琥珀酸、樟脑磺酸、顺丁烯二酸、水杨酸或α-乳酸;所述药学上可以接受的碱式盐包括下列碱中其中之一所形成的盐:锂、钠、钾等碱金属,镁、钙、等碱土金属,氢氧化锂、氢氧化钠、氢氧化钾、氢化锂、氢化钠、丁基锂、铵、三乙胺、二异丙基乙基胺、鸟氨酸、精氨酸、赖氨酸或组氨酸;所述药学上可接受的酯包括化合物中羟基或酚羟基与酸形成的酯。
本发明同时又提供了上述化合物的溶剂化混合物,所述溶剂为水、甲醇、乙醇、异丙醇、丁醇、乙酸乙酯和DMSO中的一种或两种以上的组合。
本发明同时提供了上述的化合物的制备方法,其特征在于,制备方法包括:
或者,
其中,
Y选自氮或硫时,步骤(2)合成至化合物(I′)或者,步骤(2′)合成至化合物(I″)
A、B、D、L、K、n、m、R1、R2、R4、R5、R″′、R″″、t、W、Y如权利要求1-7中任一权利要求所述;
a:α-氨基酸氨基保护方法;P表示合适的保护基,P选自叔丁氧羰基(Boc)、烯丙氧甲酰基(Alloc)、苄氧羰基、三苯甲基、苄氧基甲基、芴甲氧羰基(Fmoc)、邻苯二甲酰基、连二硫代丁二酰基、甲氧甲酰基、乙氧甲酰基、苯磺酰基、对甲基苯磺酰基、2-(三甲基硅)乙磺酰基、苄基(Bn)、三苯甲基(Tr)或烯丙基;
b:肽键合成条件;
c:与步骤a相对应的脱保护方法;
e:方法同b;
f:方法同c;
g:方法同b;
g′:还原胺化;
h:酯水解条件;
其中,“*”代表手性中心,含有“*”的所述化合物包含该结构式的所有手性构型同分异构体。
本发明另一方面提供了上述化合物用于制备预防、治疗或延缓高血压及其并发症药物的应用,所述并发症包括:冠心病、心绞痛、急性心力衰竭、慢性充血性心力衰竭、心肌梗塞及其后遗症、充血性心脏病、心肌缺血、心肌炎、心肌纤维化、心肌肥大、动脉粥样硬化、良性小动脉肾硬化症、恶性小动脉肾硬化症、血管生长异常和重塑、血管发生相关的疾病(如新血管黄斑变性)、醛固酮过多症、心律失常、肾病、糖尿病、脑卒中、血栓症、肾衰竭(如:糖尿病肾病)、高血脂、肥胖症、高血糖、视网膜动脉硬化症、高血压眼底病变中的一种或几种。
本发明另一方面又提供了一种药物组合物,该药物组合物包括:上述的化合物、权利要求1-8中任何一项所述的化合物药学上可接受的盐、上述的化合物药学上可接受的载体、赋形剂、稀释剂。
本发明另一方面还提供了上述药物组合物用于制备预防、治疗或延缓高血压及其并发症药物的应用,所述并发症包括:冠心病、心绞痛、心力衰竭(急性或慢性充血性心力衰竭)、心肌梗塞及其后遗症、充血性心脏病、心肌缺血、心肌炎、心肌纤维化、心肌肥大、动脉粥样硬化、良性小动脉肾硬化症、恶性小动脉肾硬化症、血管生长异常和重塑、血管发生相关的疾病(如新血管黄斑变性)、醛固酮过多症、心律失常、肾病、糖尿病、脑卒中、血栓症、肾衰竭(如:糖尿病肾病)、高血脂、肥胖症、高血糖、视网膜动脉硬化症、高血压眼底病变中的一种或几种。
本发明涉及的一类化合物具有抑制血管紧张素转化酶的生物活性,其本身及其药物组合物对高血压以及其他心脑血管系统疾病的预防与治疗方面的作用。
附图说明
图1为血管紧张素转化酶的浓度与OD450nm值得二次曲线拟合图;
图2为SHR大鼠灌胃221S-1a 6小时动脉收缩压变化情况;
图3为SHR大鼠灌胃不同剂量的221S-1a(1#,3#,5#)6小时内动脉收缩压的变化情况;
图4为SHR大鼠灌胃221S-1a 7天后14天内收缩压变化情况;
图5为SHR大鼠灌胃不同剂量的221S-1a(2#,4#,6#)14天内动脉收缩压的变化情况。
具体实施方式
丹参(拉丁学名:Salvia miltiorrhiza Bunge)作为传统中药的中药组成部分,一直被用作治疗心脑血管类的疾病。近期,在治疗高血压方面,关于丹参的协同增效作用,已有多篇文献报道。(Biological&Pharmaceutical Bulletin,2011,34(10),1596-1601.;Phytotherapy Research,2010,24(5),769-774.;American Journal of Physiology,2007,292(5,Pt.2),H2131-H2137.;中国临床康复,2006,10(23),73-75;Medicinal andAromatic Plants--Industrial Profiles,2000,14(Sage),193-205.)其中丹参类药物在联合普利类、沙坦类降压药,临床效果明显,特别是对高血压伴随糖尿病的患者作用显著。
丹参素是丹参水溶性提取物的主要成分,其邻苯二酚、乳酸结构,使其具有独特的抗氧化、保护心脑血管、促进血管舒张、降低血压等多种作用(Characterization of theRadical Scavenging and Antioxidant Activities of Danshensu and SalvianolicAcid B.Food and Chemical Toxicology,2008,46(1),73-81;丹参素对异丙肾上腺素损伤大鼠内皮血管活性的保护作用及机制研究.中草药,2013,1:59-64)。现已发现多酚类天然产物具有血管紧张素转化酶抑制的作用。(Angiotensin-Converting Enzyme InhibitoryEffects by Plant Phenolic Compounds:A Study of Structure ActivityRelationships.J.Agric.Food Chem.2013,61,11832-11839.;Inhibition ofAngiotesin-Converting Enzyme by Quercetin Alters the Vascular Response toBrandykinin and Angiotensin I.Pharmacology,2002,65,182-186.;Ferulic AcidImproves Cardiovascular and Kidney Structure and Function in Hypertensive Rats.J.Cardiovasc.Pharmacol.2013,61,240-249.;Tannic Acid,an Inhibitor for RenalAngiotensin Type 1 Receptor and Hypertension in Spontaneously HypertensiveRats.Endocr.Rev.2012,33,SAT-248.)本发明参考前期研究成果(CN 1868998A,β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途),将丹参素基团及其他酚酸类基团引入传统ACEI类药物骨架分子中,并结合“君-使药对”及前药的设计思想,同时引入冰片、薄荷醇等基团,设计出一类新的潜在具有血管紧张素转化酶抑制剂性能的药物前导物。
本发明参考了已公开的血管紧张素转化酶抑制剂的化学结构,如:卡托普利、依那普利、赖诺普利、培哚普利、阿拉普利、地拉普利、喹那普利、雷米普利、西拉普利、贝那普利、福辛普利、佐芬普利、群多普利、咪达普利、替莫普利、螺普利及莫希普利。
本发明还参考了已公开的关于血管紧张素转化酶抑制剂的专利文献,如:Antihypertensive mercaptoacylamino acid derivatives and their use,(1980,EP9898 A1),Preparation of converting enzyme inhibitor 5,6-dihydro[1,4]thiazino[4,3-a]quinoline-1(2H),4(4aH)-dione,(1981,US 4273927 A),[4R]-3-(ω-Aroylpropionyl)-4-thiazolidinecarboxylic acids and esters,(1983,US 4374249A)。
也参考了,1993年,WO 9302679 A1,Method of treating premenstrualsyndrome by administration of an angiotensin-converting enzyme inhibitor,其公开了下面的化合物:
也参考了,2007年,US 20070032661 A1,Process for the preparation ofintermediates of perindopril,其公开了下面的化合物:
在本发明全文中,除非另外说明,以下名称或术语的定义适用于本发明的所有内容:
术语“烷基”意指为直链或支链脂肪烃基,包含1-15个碳原子,优选的烷基含有1-6个碳原子。包括,但不限于,甲基、乙基、丙基、异丙基、
术语“取代烷基”意指烷基基团被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、环烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。
术语“烯基”意指含有至少一个C=C双键的脂肪烃基,可为直链或支链或环链,包含2至15个碳原子。优选的含有烯基的烃链具有2-8个碳原子。
术语“取代烯基”意指该烯基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、环烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。
术语“炔基”意指含有至少一个C≡C三键的脂肪烃基,可为直链或支链或环链,包含2至15个碳原子。优选的含有炔基的烃链具有2-8个碳原子。
术语“取代炔基”意指该烯基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、环烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。
术语“芳基”意指芳香族单环或多环结构,包含6-14的碳原子,优选6-12个碳原子。
术语“取代芳基”意指该芳基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、环烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。
术语“杂芳基”意指芳香族单环或多环结构,其中一个或多个环上的碳原子被其他元素取代,该其他元素包含但不限于氮、氧、硫,包含5-14的碳原子,优选5-12个碳原子。优选的杂芳基包含但不限于:吡啶基、嘧啶基、吡嗪基、哒嗪基、吲哚基、喹啉基、异喹啉基、吡唑基、呋喃基、噻吩基、噻唑基、噁唑基、吡咯基、苯并呋喃基、苯并噻吩基、
术语“取代杂芳基”意指该杂芳基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、环烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。优选的取代芳烷基包含但不限于:川芎嗪醇基。
术语“芳烷基”意指芳基-烷基基团。芳基、烷基如上文所述,优选的芳烷基包含但不限于:苄基、苯乙基。
术语“取代芳烷基”意指该芳烷基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、环烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。优选的取代芳烷基包含但不限于:对甲基苄基、细辛醇基。
术语“环烷基”意指非芳香族单环或多环结构,一般包含3至10个碳原子。优选的环烷基包含3-7个碳原子环结构但不限于:环丙基、环丁基、环戊基、环己基、环庚基。
术语“取代环烷基”意指该环烷基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。优选的取代环烷基包含3-7个碳原子环结构但不限于:右旋冰片基、左旋薄荷醇基、降冰片基。
术语“卤素”意指氟、氯、溴、碘。优选的卤素包含氟、氯、溴。
术语“杂环基”意指非芳香族的饱和单环或多环系统,环系原子一般在10个原子以内,优选4-10个还原子,其中除碳原子外还含有一个或多个非碳原子,如氮、氧、硫原子,他们可以单独或组合存在。其中,在环系统中不存在相邻的氧-氧、氧-硫或硫-硫基团。优选的杂环基包含但不限于:哌嗪基、吗啉基、硫吗啉基、哌啶基、吡咯基等。
术语取代“杂环基”意指该杂环基基团可以被一个或多个取代基取代,取代基团可以相同,也可以不相同,各取代基可独立选自烷基、芳基、氰基、硝基、卤素、烷氧基、氨基、烷基取代的1-3级氨基或环烷基取代的1-3级氨基、羟基、巯基、烷硫基、烷基酮基、羧基。优选的取代杂环基包含但不限于:N-甲基哌嗪基、3-氟哌啶基、2,6-二甲基吗啉基、2-甲基吡咯基等。
术语“杂芳烷基”意指杂芳基烷基基团,杂芳基与烷基如上所述。优选的杂芳基烷基包含但不限于:2-吡啶甲基,3-吡啶甲基,4-吡啶甲基。
术语“酰基”意指烷基-C(O)-、取代烷基-C(O)-、环烷基-C(O)-、取代环烷基-C(O)-、杂环基-C(O)-。各基团如上文所述,优选的酰基包含但不限于:乙酰基、丙酰基、环丁酰基。
术语“芳酰基”意指芳基-C(O)-、取代芳基-C(O)-。各基团如上文所述,优选的酰基包含但不限于:苯甲酰基、对甲基苯甲酰基。
术语“烷氧基”意指烷基-O-、取代烷基-O-。各基团如上文所述。优选的烷氧基包含但不限于:甲氧基、乙氧基、异丙基、右旋冰片氧基、左旋薄荷醇氧基、2,3,4-三甲氧基苯-2′-烯基丙氧基(细辛醇氧基)、川芎嗪氧基。
术语“芳烷氧基”意指芳烷基-O-、取代芳烷基-O-。各基团如上文所述。优选的芳烷氧基包含但不限于:苯甲氧基、2,3,4-三甲氧基苯-2′-烯基丙氧基(细辛醇氧基)。
术语“芳氧基”意指芳基-O-、取代芳基-O-。各基团如上文所述。优选的芳氧基包含但不限于:苯氧基、对甲基苯氧基。
术语“烷硫基”意指烷基-硫-基团,其中烷基部分如上所述。优选的烷硫基包含但不限于:甲硫基、乙硫基、丙硫基。
术语“芳烷硫基”意指芳烷基-硫-基团,其中芳烷基基团如上所述。优选的芳烷硫基包含但不限于:苯甲硫基、苯乙硫基。
术语“芳硫基”意指芳基-硫-基团,其中芳基基团如上所述。优选的芳硫基包含但不限于:苯硫基。
术语“烷基磺酰基”意指烷基-S(O2)-基团。烷基如上文所述。优选的烷基磺酰基包含但不限于:甲基磺酰基、乙基磺酰基。
术语“芳基磺酰基”意指芳基-S(O2)-基团。芳基如上文所述。优选的芳基磺酰基包含但不限于:苯磺酰基、萘磺酰基。
术语“至少一种”意指一种或多种。
术语“取代的”指选自指定的基团代替在指定的原子上的一个或多个氢,并符合指定原子的正常价态,且产生的化合物稳定。
术语“任意取代的”指根据需要,在满足取代的条件下,选用指定的基团、原子团或部分取代。
3.盐、溶剂化合物
本发明所设计的三肽及其类似物还包含其“前药”、“溶剂合物”、“盐”(包括:“酸式盐”、“碱式盐”和内盐)和“酯”。这些三肽类化合物的“前药”、“溶剂合物”和“盐”均在本发明范围内。其中,“溶剂合物”和“盐”等同于相应化合物的游离形式。
其中,术语“前药”意指药物前体的化合物,可通过代谢或体内化学转化成为通式(I)的化合物或其盐或其溶剂合物或其酯。
其中,术语“溶剂合物”意指本发明化合物与一种或多种溶剂分子的物理缔合。该物理缔合涉及各种程度的离子和共价键结合,包括氢键、范德华力等作用。其中,“溶剂合物”由两部分组成:溶液相和可分离溶剂合物两者。适当的溶剂合物包含但不限于:水合物、甲醇合物、乙醇、DMSO、乙酸乙酯合物。
术语“盐”包括酸式盐、碱式盐和内盐。意指本发明中设计的三肽类化合物(通式(I))与无机酸或有机酸所形成的酸式盐,与无机碱或有机碱所形成的碱式盐,以及三肽类化合物(通式(I))中含有的碱性基团(如氨基、胍基、咪唑基、吲哚基等)与酸性基团(如羧酸、烷基磺酸、磷酸等)所形成的内盐。
其中,形成酸式盐的酸包含但不限于以下酸:
硫酸、硫酸氢、盐酸、氢溴酸、磷酸、硝酸、碳酸、硼酸、甲磺酸、苯磺酸、对甲基苯磺酸、甲酸、乙酸、丙酸、丁酸、丙酮酸、马来酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、苯甲酸、樟脑酸、富马酸、草酸、琥珀酸、樟脑磺酸、顺丁烯二酸、水杨酸和α-乳酸。此外,由P.Stahl,Camille G.编辑的《Handbook of Pharmaceutical Salts.Properties,Selection andUse》,2002,Zurich:Wiley-VCH中介绍的药学上可以接受的形成盐的酸也可引用结合到本发明专利中。
其中,形成碱式盐的碱包含但不限于以下碱:
锂、钠、钾等碱金属,镁、钙、等碱土金属,氢氧化锂、氢氧化钠、氢氧化钾、氢化锂、氢化钠、丁基锂、铵、三乙胺、二异丙基乙基胺、鸟氨酸、精氨酸、赖氨酸、组氨酸等碱性氨基酸。
另外,本发明三肽类化合物所形成的药学上可以接受的酯,意指化合物中的羟基或酚羟基与羧酸(包含但不限于:烷基羧酸、取代烷基羧酸、芳基羧酸、取代芳基羧酸、芳烷基羧酸、取代芳烷基羧酸、环烷基羧酸、取代环烷基羧酸、杂环基羧酸、杂芳烷基羧酸,例如:乙酸酯、丙酸酯、苯甲酸酯、烟酸酯)形成的羧酸酯;还包括,化合物中的羟基或酚羟基与磺酸(包含但不限于:烷基磺酸、芳基磺酸、取代芳基磺酸酯,例如:甲磺酸酯、苯磺酸酯、对甲基苯磺酸酯)形成的磺酸酯;还包括,化合物中的羟基或酚羟基与氨基酸(包含但不限于:α-氨基酸、β-氨基酸、ω-氨基酸,例如丙氨酸酯、谷氨酸酯)形成的酯;还包括,化合物中的羟基或酚羟基与磷酸、单烷基磷酸、二烷基磷酸、亚磷酸(例如亚磷酸二乙酯)形成的磷酸酯。
另外,本发明三肽化合物及其药学上可接受的(无毒性、生理学上课接受的)“溶剂合物”、“盐”(包括:“酸式盐”、“碱式盐”和内盐)、“酯”,还有相关的“前药”,所涉及的对映体、立体异构体、旋转异构体、互变异构体、位置异构体和外消旋体均在本发明范围之内。
另外,在合成过程中可能保护所关注分子上的敏感货反应性的基团。代表性的保护基在T.W.Greene和P.G.M.Wuts“Protective Groups in Organic Synthesis”JohnWiley&Sons,Inc.,New York,1999中叙述,其全部内容引入本发明作为参考。可以利用本领域公知的方法添加或去除相应的保护基。
4.药物组合物
术语“组合物”意指涵盖包含特定量的特定成分的产品,以及由特定量的特定成分的组合二直接或间接形成的任何产品。
“哺乳动物”意指人及其他哺乳动物。
“患者”包括人和动物。
“有效量”意指本发明所述的化合物或药物组合物的量在抑制血管紧张素转化酶上是有效的,并因此产生所需的预防、治疗、改善或抑制的效果。
“药学上可以接受的载体”意指具有用于配制本发明组合物的足够纯度和质量的化合物和组合物,在适当地给动物或人时,不产生不良反应,用作药物的载体。
“药学上可以接受的稀释剂”意指具有用于配制本发明组合物的足够纯度和质量的化合物和组合物,在适当地给动物或人时,不产生不良反应,用作药物的稀释剂。
药用组合物一般至少包括一种本发明化合物和一种或一种以上的药学上可接受的载体。其中,固体剂型可包含:填充剂(如淀粉、微晶纤维素、蔗糖、葡萄糖、乳糖、山梨醇、甘露糖醇等)、粘合剂(明胶、羧甲基纤维素、海藻酸盐、阿拉伯胶)、保湿剂(甘油)、崩解剂(碳酸钙、淀粉、琼脂、海藻酸)、溶解延迟剂(石蜡)、吸收促进剂(季铵盐化合物)、湿润剂(十六醇、单硬脂酸甘油酯)、吸附剂(高岭土、膨润土)、润滑剂(滑石粉、固体聚乙二醇、硬脂酸钾、钙或镁盐、月桂基硫酸钠,其中水溶性润滑剂包括:氯化钠、乙酸钠、苯甲酸钠油酸钠)、着色剂(粘土、氧化铝)及缓冲剂。
本发明的化合物可按照常规制药工艺制成合适的剂型,如片剂、胶囊。
5.病症和疾病
本发明的化合物(I)及其药学上可接受的(无毒性、生理学上课接受的)盐、酯、药物组合物适用于预防、治疗或延缓以下心脑血管疾病特别是与高血压相关及其并发症。
所述病症和疾病包括:高血压、冠心病、心绞痛、心力衰竭(急性或慢性充血性心力衰竭)、心肌梗塞及其后遗症、充血性心脏病、心肌缺血、心肌炎、心肌纤维化、心肌肥大、动脉粥样硬化、良性小动脉肾硬化症、恶性小动脉肾硬化症、血管生长异常和重塑、血管发生相关的疾病(如新血管黄斑变性)、醛固酮过多症、心律失常、肾病、糖尿病、脑卒中、血栓症、肾衰竭(如:糖尿病肾病)、高血脂、肥胖症、高血糖、视网膜动脉硬化症、高血压眼底病变中的一种或几种。
6.本发明中所涉及的细辛醇制备方法包括:
(1)化合物V与化合物VI在脂肪醇的存在下经催化剂催化反应得到化合物VII:
其中R1选自C1-C5的直链或支链烷基;
(2)还原化合物VII得到化合物VIII:
步骤(1)是将化合物VI与脂肪醇先在二甲苯、甲苯或苯中回流反应3-12小时,进一步可选4-10个小时,冷却至室温后,加入2,4,5-三甲氧基苯甲醛(化合物V)与催化剂,再回流反应5-24小时,进一步可选8-14小时,得到化合物VII;步骤(1)中所使用的脂肪醇为甲醇、乙醇、丙醇、异丙醇、丁醇、异丁醇、正戊醇和异戊醇中的一种或其中任意组合,进一步可选甲醇和乙醇;中的一种或其中任意组合脂肪醇与化合物VI的摩尔比率在1∶1~1∶10,进一步可选脂肪醇与化合物VI的摩尔比率为1∶1~1∶4;所用的催化剂为吡啶、2,4,6-三甲基吡啶、2,6-二甲基吡啶、2,6-二叔丁基-4-甲基吡啶、4-二甲氨基吡啶、哌啶和四氢吡咯中的一种或其中任意组合;催化剂与2,4,5-三甲氧基苯甲醛的摩尔比率在0.1∶1~2∶1。
步骤(2)所用还原剂为硼氢化钠、二氢双(2-甲氧乙氧基)铝酸钠、氢化铝锂或二异丁基氢化铝;还原剂与化合物VII的比率为1∶1~10∶1;所用溶剂为四氢呋喃、1,4二氧六环、二甲基乙二醚、甲苯、苯、二甲苯、乙醚、甲基叔丁基醚、二氯甲烷、二氯乙烷、三氯甲烷、四氯甲烷和正己烷中的一种或其中任意组合;反应温度在-78℃~25℃;反应时间在0.5~24小时之间。
缩写:
EDCI 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐
DCC 二环己基碳二亚胺
Alloc 烯丙氧甲酰基
Fmoc 芴甲氧羰基
Bn 苄基三苯甲基
Tr 三苯甲基
HOBt 1-羟基苯并三氮唑
THF 四氢呋喃
EtOAc 乙酸乙酯
MeOH 甲醇
EtOH 乙醇
TFA 三氟乙酸
DCM 二氯甲烷
DIPEA 二异丙基乙胺
DMF N,N-二甲基乙酰胺
DMSO 二甲基亚砜
DMAP 4-N,N-二甲基吡啶
HATU 2-(7-偶氮苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯
PyBOP 1H-苯并三唑-1-基氧三吡咯烷基六氟磷酸盐
Boc 叔丁氧羰基
Cbz 苄氧羰基
NMR 核磁共振
MS 质谱
以下提供制备和实例加以说明本发明的具体实施例。除非特别说明,否则这些具体实施例并不打算以任何方式限制本发明的范围,其实施例中使用的各种原料、方法完全在本领域技术人员的知识范围内。
实施例1:
步骤一:
1000毫升三口烧瓶,带温度计,分别加入L-脯氨酸(115.1g,1.0mol)、1,4-二氧六环(300mL)、2mol/L氢氧化钠水溶液(400mL),冷却至0℃,搅拌10分钟,再滴加二碳酸二叔丁酯(283.8g,1.3mol)(60分钟内滴完),缓慢升温,室温下搅拌6小时或过夜。反应液用4mol/L稀盐酸调节pH=4,用乙酸乙酯/水体系萃取、洗涤3次,合并有机相,无水硫酸钠干燥,得221S-1a-1白色固体189.2克,产率88%。
步骤二:
500毫升三口烧瓶,带温度计,分别加入221S-1a-1(2.15g,10mmol)、四氢呋喃(35mL)、D-冰片(1.39g,9mmol)、DMAP(0.12g,1mmol),冷却至0℃,搅拌5分钟,分步加入EDCI(2.30g,12mmol)(15分钟内加完),缓慢升温,室温下24小时。反应液用乙酸乙酯/水体系萃取、洗涤3次,合并有机相,无水硫酸钠干燥,抽滤,所得固体经硅胶色谱柱分离得到2.28克221S-1a-2,产率60%。
步骤三:
500毫升单口烧瓶,分别加入221S-1a-2(3.51g,10mmol)、三氟乙酸(8mL)、二氯甲烷(16mL),氮气保护下,室温搅拌5小时,减压浓缩后,加入乙酸乙酯(50mL),水(50mL),饱和碳酸氢钠水溶液(50mL),萃取分离3次,合并有机相,无水硫酸钠干燥,抽滤,减压浓缩,得到浅黄色油状物或半固体221S-1a-3 2.2克,产率88%。产品无须进一步纯化,直接进入下一步反应。
步骤四:
250毫升单口烧瓶,分别加入221S-1a-3(2.51g,10mmol)、N-Boc-Ala(2.08g,11mmol)、二氯甲烷(50mL),HOBT(1.49g,11mmol),EDCI(2.30g,12mmol),氮气保护下,室温搅拌过夜,减压浓缩后,加入乙酸乙酯(50mL),水(50mL),饱和碳酸氢钠水溶液(50mL),萃取分离3次,合并有机相,无水硫酸钠干燥,抽滤,减压浓缩,所得粗品经硅胶色谱柱分离得到浅黄色油状物221S-1a-43.85克,产率91.2%。
MS m/z=[M+1]423.2900
1H NMR(600MHz,CDCl3)δ5.39(d,J=8.0Hz,1H),4.96(d,J=9.7Hz,1H),4.56(dd,J=8.4,3.9Hz,1H),4.52-4.44(m,1H),3.65-3.58(m,1H),2.38-2.30(m,1H),2.27-2.20(m,1H),2.09-1.97(m,3H),1.90-1.84(m,1H),1.77-1.72(m,1H),1.70-1.67(m,1H),1.43(s,9H),1.36(d,J=6.9Hz,3H),1.33-1.21(m,3H),1.03(dd,J=13.8,3.3Hz,1H),0.89(s,3H),0.86(s,3H),0.80(s,3H).
步骤五:
按照实施例1步骤三,投4.22g 221S-1a-4得到浅黄色或类白色固体221S-1a-52.93g克,产率91%。产品无须进一步纯化,直接进入下一步反应。
MS m/z=[M+1]323.2386
1H NMR(600MHz,cdcl3)δ4.94(d,J=9.7Hz,1H),4.54(dd,J=8.6,4.4Hz,1H),4.34(d,J=6.7Hz,1H),3.69-3.63(m,1H),3.59-3.54(m,1H),2.36-2.27(m,2H),2.13-2.00(m,4H),1.83-1.74(m,2H),1.72-1.68(m,1H),1.56(d,J=7.0Hz,3H),1.51(d,J=6.9Hz,1H),1.34-1.27(m,1H),1.26-1.20(m,1H),0.97(dd,J=13.8,3.2Hz,1H),0.89(s,3H),0.87(s,3H),0.78(s,3H).
步骤六:
100毫升单口烧瓶,分别加入221S-1a-5(0.322g,1.0mmol)、D-丹参素(0.22g,1.1mmol)、N,N-二甲基甲酰胺(5mL)/六甲基磷酰胺(5mL),HOBT(0.15g,1.1mmol),EDCI(0.18g,1.3mmol),氮气保护下,室温搅拌36小时,加入乙酸乙酯(50mL),水(50mL),饱和碳酸氢钠水溶液(50mL),萃取分离3次,合并有机相,无水硫酸钠干燥,抽滤,减压浓缩,所得粗品经硅胶色谱柱分离得到类白色或浅白色泡沫状固体221S-1a 0.28克,产率56%。
MS m/z=[M+1]:503.0
1H NMR(600MHz,CDCl3)δ8.16(s,1H),7.42(d,J=8.1Hz,1H),6.81(d,J=8.0Hz,1H),6.71(s,1H),6.65(d,J=9.8Hz,1H),5.85(s,1H),4.93(d,J=9.0Hz,1H),4.81-4.73(m,1H),4.31-4.26(m,1H),4.23(dd,J=8.6,4.3Hz,1H),3.81(dd,J=17.0,7.3Hz,1H),3.68-3.59(m,1H),3.34(d,J=4.6Hz,1H),3.10(dd,J=14.1,3.9Hz,1H),2.96(dd,J=14.1,8.1Hz,1H),2.37-2.31(m,1H),2.25-2.17(m,1H),2.12-2.01(m,2H),1.98-1.92(m,1H),1.90-1.84(m,1H),1.79-1.73(m,1H),1.68(t,J=4.4Hz,1H),1.40(d,J=7.0Hz,3H),1.35-1.20(m,3H),1.02(dd,J=13.8,3.4Hz,1H),0.88(s,3H),0.86(s,3H),0.80(s,3H).
13C NMR(600MHz,CDCl3)δ173.49(s),171.96(s),171.74(s),144.03(s),143.97(s),128.27(s),121.54(s),116.89(s),115.15(s),81.17(s),72.79(s),59.51(s),49.08(s),48.10(s),47.32(s),46.48(s),44.95(s),39.81(s),36.64(s),29.30(s),28.14(s),27.29(s),24.94(s),19.82(s),18.94(s),17.71(s),13.70(s),0.15(s).
步骤七:
100毫升单口烧瓶,分别加入221S-1a(0.251g,0.5mmol)、氢氧化锂(0.05g,2.0mmol)、水∶甲醇∶四氢呋喃=3∶1∶1(10mL),氮气保护下,室温搅拌16小时,加入乙酸乙酯(30mL),水(30mL),萃取分离3次,合并有机相,无水硫酸钠干燥,抽滤,减压浓缩,所得粗品经硅胶色谱柱分离得到类白色或浅白色泡沫状固体221S-1a-6 0.14克,产率76%。MS m/z=[M+1]:366.9
根据上述实施例1中所描述的程序,替换适当的起始原料和试剂制备出通式(I)的下列化合物
实施例2-28:
表1
其中,221S-2a、221S-144a合成过程中所用偶联试剂为7a合成过程中所用偶联试剂为HATU,所用碱为DIPEA;221S-119a合成过程中所用偶联试剂为PyBOP;221S-11a,221S-12a合成过程中所用偶联试剂为DCC。
其中,关键中间体左旋丹参素的合成参考文献(CN 103288630),川芎嗪醇的合成参考文献(Journal of Natural Products,2012,75(9),1589-1594.),环己烷并脯氨酸的合成参考文献(Org.Biomol.Chem.,2012,10,2840-2846),细辛醇的合成路线如下:
i:(1)甲醇、甲苯,110℃,4小时;(2)吡啶,六氢吡啶,回流18小时;j:LiAlH4,THF,冰,AlCl3,0℃,30分钟
实施例29:
步骤一:
500毫升三口烧瓶,带温度计,分别加入N-Cbz脯氨酸(2.49g,10mmol)、DCM(50mL)、1-甲基哌嗪(1.10g,11mmol)、DMAP(0.12g,1.0mmol),冷却至0℃,搅拌5分钟,分步加入EDCI(2.30g,12mmol)(15分钟内加完),缓慢升温,室温下24小时。反应液用乙酸乙酯/水体系萃取、洗涤3次,合并有机相,无水硫酸钠干燥,抽滤,所得固体经硅胶色谱柱分离得到221S-151a-12.91克,产率88%。
步骤二:
500毫升三口烧瓶,分别加入221S-151a-1(1.66g,5mmol)、钯碳(0.16g)、甲醇(25mL),通入氢气,常压,室温搅拌24小时。过滤除掉钯碳,减压旋蒸,所得油状物经硅胶色谱柱分离得到221S-151a-20.89克,产率90%。
步骤三:
500毫升三口烧瓶,带温度计,分别加入221S-151a-2(1.97g,10mmol)、DCM(50mL)、N-Cbz丙氨酸(2.45g,11mmol)、DMAP(0.12g,1.0mmol),冷却至0℃,搅拌5分钟,分步加入EDCI(2.30g,12mmol)(15分钟内加完),缓慢升温,室温下24小时。反应液用乙酸乙酯/水体系萃取、洗涤3次,合并有机相,无水硫酸钠干燥,抽滤,所得固体经硅胶色谱柱分离得到221S-151a-3 3.26克,产率81%。
步骤四:
同实施例29步骤二,投221S-151a-34.02克,得到221S-151a-4 2.01克,产率75%。
步骤五:
同实施例1步骤六,投221S 151a-4 0.27克得到221S 151a 0.27克,产率61%。
步骤六:
500毫升三口烧瓶,分别加入221S-151a(0.45mg,1mmol)、甲醇(25mL),冷却至0℃,搅拌5分钟,缓慢通入盐酸气体,2-4℃搅拌4小时。抽滤,所得白色固体为221S-151a-5 0.40克,产率83%。
其他含有胺类的化合物,可用同样的方法制成盐酸盐。此外其他酸式盐,也可用类似的方法,在含有胺类化合物的溶剂中,缓慢加入相应的酸,低温(2-4℃)或室温搅拌2-10小时得到相应的酸式盐。
实施例30-35:
根据上述实施例29中所描述的方法,替换适当的起始原料和试剂制备出通式(I)的下列化合物:
表2
其中,221S-153a合成过程中脯氨酸、丙氨酸均用Boc保护,脱Boc反应均按照实施例1,步骤二进行。
实施例36:
步骤一:
N-Boc脯氨酸(21.5g,0.1mol),DCC(20.6g,0.1mol),DMAP(1.22g,0.01mmol)依次加入含有150mL的DMF中。该反应体系在室温搅拌10分钟后,冷至0℃。再滴加乙硫醇(6.82g,0.11mol),反应过夜。向反应体系中加200mL水淬灭反应。过滤,滤饼用乙酸乙酯洗涤,出去DCU。合并有机相,依次用饱和碳酸钠水溶液(20mL×3)、水、饱和氯化钠水溶液洗涤,无水硫酸镁干燥,过滤,浓缩。低压色谱柱层析纯化得产品221S-177a-1 18.4g,产率71%。
步骤二:
221S-177a-1(2.59g,10mmol)溶于EtOAc(25mL),搅拌均匀后,于室温下通入HCl气体30分钟。再用氮气吹出剩余的HCl气体,减压旋蒸,真空干燥的白色固体221S-177a-21.66g,产率85%。
步骤三:
250毫升单口烧瓶,分别加入221S-177a-2(1.95g,10mmol)、N-Boc-丙氨酸(2.08g,11mmol)、DCM(30mL),HOBT(1.49g,11mmol),EDCI(2.30g,12mmol),氮气保护下,室温搅拌过夜,减压浓缩后,加入乙酸乙酯(50mL),水(50mL),饱和碳酸氢钠水溶液(50mL),萃取分离3次,合并有机相,无水硫酸钠干燥,抽滤,减压浓缩,所得粗品经硅胶色谱柱分离得到浅黄色油状物221S-177a-3 2.51克,产率76%。
步骤四:
同实施例1,步骤五,投3.3g 221S-177a-3,得到类白色固体221S-177a-4 1.66克,产率74%。产品无须进一步纯化,直接进入下一步反应。MS ESI+ve m/z:231.9。
步骤五:
同实施例1,步骤六,投0.23g 221S-177a-4,得到221S-177a 0.22克,产率51%。MSESI+ve m/z:411.2。
实施例37:
步骤一:
N-Boc脯氨酸(2.15g,10mmol)溶于干燥的THF(40mL),再加入2,2′-二硫吡啶(2.20g,10mmol),三苯基膦(3.14g,12mmol)。室温搅拌3小时。用乙酸乙酯/水体系萃取分离。有机相,再用水、饱和氯化钠水溶液洗涤,无水硫酸镁干燥,过滤,浓缩。低压色谱柱层析纯化得产品221S-181a-1 2.46克,产率80%。
步骤二:
同实施例1,步骤三,投3.08g 221S-181a-1,得到221S-181a-2 1.62克,产率78%。MS ESI+ve m/z:209.0。
步骤三:
同实施例1,步骤四,投2.08g 221S-181a-2,得到221S-181a-3 3.31克,产率87%。MS ESI+ve m/z:379.9。
步骤四:
同实施例1,步骤三,投3.80g 221S-181a-3,得到221S-181a-4 2.0克,产率73%。MS ESI+ve m/z:279.9。
步骤五:
同实施例1,步骤六,投0.28g 221S-181a-4,得到221S-181 0.22克,产率48%。MSESI+ve m/z:460.0。
实施例38:
步骤一:
250毫升单口烧瓶,分别加入221S-1a-5(0.32g,1.0mmol)、原儿茶醛(0.166g,1.2mmol)、二氯乙烷(25mL),氰基硼氢化钠(0.10g,1.5mmol),醋酸2滴,氮气保护下,室温6小时,减压浓缩后,加入乙酸乙酯(50mL),水(50mL),饱和碳酸氢钠水溶液(50mL),萃取分离3次,合并有机相,无水硫酸钠干燥,抽滤,减压浓缩,所得粗品经硅胶色谱柱分离得到浅黄色油状物221S-211 0.15克,产率34%。
步骤二:
同实施例1,步骤七,投0.44g 221S-211,得到221S-211-1 0.16克,产率52%。MSESI+ve m/z:309.2。
本发明中所描述的具体实施例仅为对本发明精神举例说明。本发明所属技术领域的技术人员可以对所描述的具体实施例做各种各样的修改或补充或采用类似的方式代替,但并不偏离本发明的精神或超越所附权利要求书所定义的范围。
本发明LC-MS测试方法:
LC-QTOF MS&MS/MS条件:HPLC设备:Agilent 1200 Infinity LC;色谱柱:AgilentHC-C18 4.6×250mm,5μm;流速:0.6mL/min.;柱温:30℃;流动相:A-H2O,0.1%乙酸/B-甲醇,A∶B=20∶80;MS设备:Agilent 6520 QTOF;离子源:Dual ESI;离子模式:正;离子喷雾电压:3500V;干气温度:350℃;干气流速:10.0L/min.(N2);喷雾器压力:45psi(N2);碎裂器电压:130V;碰撞能量:分别为10,25,40eV。
本发明涉及新的血管紧张素转化酶抑制剂。其生物学活性通过下列体内、体外测定进一步描述。
血管紧张素转化酶(ACE)活性的测定
体外测定ACE活性
高效液相色谱法测定:参照Cushman等(Biochemical Pharmacology,1971,20(7):1637-1648.;Journal of Dairy Science,1995,78(4):777-783.)方法,并在报道的方法对本发明的化合物进行血管紧张素转化酶活性的测定。该法以适合连续监视ACE活性的Ang I的模拟物马尿酰-组氨酰-亮氨酸(HHL)的水解产物马尿酸(Hip)的含量为基础。当加入ACE抑制剂时,可抑制反应的进行,从而减少马尿酸的生成。因此,通过测定加入抑制剂前后所生成的马尿酸在228nm处紫外吸光度的变化得出ACE抑制活性。
材料和方法:
(1)材料:
实验仪器:
表3体外活性实验仪器
实验试剂:
表4体外活性实验试剂
(2)实验方法
取25μL样品溶液(溶于pH=8.3的50mM的HEPES盐酸缓冲液,其中含300mM的NaCl,样品量为50μmol)和200μL 0.3%底物HHL(溶于相同的缓冲液中)于37℃保温6min,加入50μL ACE(0.5U溶于1.5mL相同缓冲液中),37℃下反应15min后,加入250μL,1mol/L的盐酸终止反应,混匀,放置5min后,加入2mL乙酸乙酯,强力振荡60s,1000×g离心10min。上清液置沸水浴15min,加入3mL去离子水,混匀,静置。取20μL反应物进样,通过反相高效液相色谱检测马尿酸。以马尿酸的生成量判断样品对ACE的抑制作用,同时用缓冲液代替样品溶液做空白对照。样品对ACE抑制率(%)=(对照品马尿酸峰值-样品马尿酸峰值)/对照品马尿酸峰值×100%。
色谱条件:
紫外检测器;检测波长:228nm;色谱柱:Agilent HC-C184.6×250mm,5μm;流速:1.0mL/min;进样量:20μL;柱温:30℃;流动相:乙睛-水(80/20)。结果如表5所示:
表5
体内测定ACE含量
材料和方法:
实验仪器:
表6体内活性测试实验仪器
实验材料:
表7体内活性实验材料及试剂
实验原理:
双抗体夹心ELISA法测定ACE含量:用抗小鼠ACE抗体包被于酶标板上,实验时样品或标准品中的小鼠ACE会与包被抗体结合,游离的成分被洗去。依次加入生物素化的抗小鼠ACE抗体和辣根过氧化物酶标记的亲和素。抗小鼠ACE抗体与结合在包被抗体上的小鼠ACE结合、生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450nm波长处测OD值,ACE浓度与OD450值之间呈二次非线性关系,通过绘制标准曲线计算出样品中ACE的浓度。
实验方法:
(1)实验动物处理方法:
取雄性昆明小鼠108只,体重(bw,20士2g),随机分为18组,每组6只。分别为正常对照组,阳性对照药卡托普利组,化合物221S组。每天灌胃一次,按0.05mmol/kg灌胃(体积10ml/kg),连续给药7天。末次灌胃给药2h后,断颈处死,取心、肝、脑、肺、肾、血,其中肾用于本实验检测,其他组织样品用于另外实验检测。将肾脏用PBS稀释10倍,匀浆,离心,取上清用于测定或存于-20℃备用。
(2)ELISA操作方法:
采用ELISA检测小鼠肾脏组织中ACE的含量,所有步骤均严格按照说明书进行,主要步骤如下:
(a)加样:分别设空白孔(空白对照孔不加样品及酶标试剂,其余各步操作相同)、标准孔、待测样品孔。余孔分别加不同浓度的标准溶液或待测样品100μL,注意不要有气泡,轻轻混匀。酶标板加上盖,37℃反应90min。
(b)弃去液体,甩干,不用洗涤。每个孔中加入生物素化抗体工作液100μL(在使用前15分钟内配制),酶标板加上覆膜,37℃温育1小时。
(c)弃去孔内液体,甩干,洗板3次,每次浸泡1-2分钟,大约350μL/每孔,甩干并在吸水纸上轻拍将孔内液体拍干。
(d)每孔加酶结合物工作液(临用前15分钟内配制)100μL,加上覆膜,37℃温育30分钟。
(e)弃去孔内液体,甩干,洗板5次,方法同步骤(c)。
(f)每孔加底物溶液(TMB)90μL,酶标板加上覆膜37℃避光孵育15分钟左右(根据实际显色情况酌情缩短或延长,但不可超过30分钟。当标准孔出现明显梯度时,即可终止)。
(g)每孔加终止液50μL,终止反应,此时蓝色立转黄色。终止液的加入顺序应尽量与底物溶液的加入顺序相同。
(h)立即用酶标仪在450nm波长测量各孔的光密度(OD值)。应提前打开酶标仪电源,预热仪器,设置好检测程序。
实验结果如图1所示,公式:y=ax2+bx+c;其中,a:-0.0052;b:0.2556;c:-0.0233;R2:0.9968。
体内活性(ELISA法)结果如表8所示:
表8
实验结果表明,本发明化合物能够降低大鼠血浆ACE酶的含量,且降低幅度均大于阳性药卡托普利,其中化合物221S-1a降低作用最为显著。
自发性高血压大鼠(SHR)血压的测定
实验仪器与试剂
实验仪器:
表9体内活性测试实验仪器
实验材料:
表10体内活性实验材料及试剂
实验方法:
SPF级雄性自发性高血压模型大鼠(SHR),雄性,12周龄,体重200g±20g。分为三组:空白组、对照组和样品组,每组6只。饲养于西北大学生命科学院陕西省生物医药动物实验室,温度22℃,湿度50%,12小时光照/黑暗交替,自由摄食进水。SHR大鼠适应环境5天后,开始训练大鼠以适应血压测量。给药前,测定各组SHR大鼠基础血压,收缩压在190±5mmHg之间。
(1)一次给药SHR大鼠血压的测定:
实验大鼠收缩压的测定采用尾脉搏间接测压法。
对SHR大鼠实施灌胃,样品与对照品(卡托普利)均溶于含1%吐温80的蒸馏水中,空白对照组灌胃同体积含1%吐温80的蒸馏水。按0.05mmol/kg灌胃(体积10ml/kg),灌胃后分别于1h、2h、3h、4h、6h各测一次血压。
具体测量步骤:将清醒的大鼠放入血压仪的固定盒中,固定盒底部置30℃的加热板,预热10min,以扩张局部血管。待大鼠处于安静状态后,将可充气管状尾套管环绕SHR的鼠尾根部,并将压力电子脉搏检测器置于大鼠尾根部,电脑屏幕产生信号,稳定后测定血压值,记录血压变化小于10mmHg的5次读数,记录数值间隔10秒。取其均值作为该大鼠的收缩压。
(a)SHR大鼠灌胃221S-1a 6小时动脉收缩压变化情况如图2所示。
(b)SHR大鼠灌胃不同剂量的221S-1a 6小时内动脉收缩压的变化情况如图3所示。
结果显示,化合物221S-1a对SHR大鼠表现出较好的降压效果,具有较好的剂量依赖性,降压效果要好于卡托普利。
(2)多次给药SHR大鼠血压的测定:
按上述方法与剂量,连续灌胃7天,每天1次,给药2小时后测量血压。停药后,继续测量血压7天,每天1次,记录血压变化。
(a)SHR大鼠灌胃221S-1a 7天后14天内收缩压变化情况如图4所示。
(b)SHR大鼠灌胃不同剂量的221S-1a 14天内动脉收缩压的变化情况如图5所示。
长期对SHR大鼠口服给化合物221S-1a 7天后,停止给药,记录14天内血压变化,结果显示:化合物221S-1a具有明显的降压效果,降压效果好于卡托普利。不同剂量的221S-1a对SHR大鼠的动脉收缩压的影响有明显的剂量依赖性。
Claims (5)
2.权利要求1中任一权利要求所述化合物的对映体、立体异构体、非对映异构体或外消旋体。
3.权利要求1或2所述化合物用于制备预防、治疗或延缓高血压及其并发症药物的应用,所述并发症包括:冠心病、心绞痛、急性心力衰竭、慢性充血性心力衰竭、心肌梗塞及其后遗症、充血性心脏病、心肌缺血、心肌炎、心肌纤维化、心肌肥大、动脉粥样硬化、良性小动脉肾硬化症、恶性小动脉肾硬化症、血管生长异常和重塑、醛固酮过多症、心律失常、肾病、糖尿病、脑卒中、血栓症、高血脂、肥胖症、高血糖、视网膜动脉硬化症、高血压眼底病变中的一种或几种。
4.一种药物组合物,其特征在于,该药物组合物包括:权利要求1或2所述的化合物、权利要求1或2所述的化合物药学上可接受的盐、权利要求1或2所述的化合物药学上可接受的载体、赋形剂、稀释剂。
5.权利要求4所述药物组合物用于制备预防、治疗或延缓高血压及其并发症药物的应用,所述并发症包括:冠心病、心绞痛、心力衰竭、心肌梗塞及其后遗症、充血性心脏病、心肌缺血、心肌炎、心肌纤维化、心肌肥大、动脉粥样硬化、良性小动脉肾硬化症、恶性小动脉肾硬化症、血管生长异常和重塑、醛固酮过多症、心律失常、肾病、糖尿病、脑卒中、血栓症、高血脂、肥胖症、高血糖、视网膜动脉硬化症、高血压眼底病变中的一种或几种。
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410705180.3A CN105693817B (zh) | 2014-11-27 | 2014-11-27 | 一类三肽化合物及其制备方法与应用 |
KR1020177017351A KR102098783B1 (ko) | 2014-11-27 | 2015-11-27 | 트리펩티드 화합물, 이의 제조방법 및 이의 용도 |
PL15863217T PL3225627T3 (pl) | 2014-11-27 | 2015-11-27 | Mieszanka tripeptydowa, sposób jej wytwarzania i jej zastosowanie |
ES15863217T ES2897916T3 (es) | 2014-11-27 | 2015-11-27 | Compuesto tripéptido, método de preparación del mismo y aplicación del mismo |
MYPI2017701895A MY193996A (en) | 2014-11-27 | 2015-11-27 | Tripeptide compound, preparation method therefor, and application thereof |
EP15863217.4A EP3225627B9 (en) | 2014-11-27 | 2015-11-27 | Tripeptide compound, preparation method therefor, and application thereof |
AU2015353118A AU2015353118B2 (en) | 2014-11-27 | 2015-11-27 | Tripeptide compound, preparation method therefor, and application thereof |
DK15863217.4T DK3225627T5 (da) | 2014-11-27 | 2015-11-27 | Tripeptidforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
US15/529,633 US11358985B2 (en) | 2014-11-27 | 2015-11-27 | Tripeptide compound, preparation method therefor, and application thereof |
NZ732301A NZ732301A (en) | 2014-11-27 | 2015-11-27 | Peptide compound, preparation method therefor, and application thereof |
CA2968595A CA2968595C (en) | 2014-11-27 | 2015-11-27 | Tripeptide compound having angiotensin converting enzyme inhibiting activity, preparation method thereof, and application thereof |
PCT/CN2015/095758 WO2016082786A1 (zh) | 2014-11-27 | 2015-11-27 | 一类三肽化合物及其制备方法与应用 |
RU2017121590A RU2685709C2 (ru) | 2014-11-27 | 2015-11-27 | Трипептидное соединение, способ его получения и его применение |
JP2017527865A JP6689848B2 (ja) | 2014-11-27 | 2015-11-27 | トリペプチド化合物、その調製方法及びその用途 |
SG11201704235SA SG11201704235SA (en) | 2014-11-27 | 2015-11-27 | Tripeptide compound, preparation method therefor, and application thereof |
SI201531768T SI3225627T1 (sl) | 2014-11-27 | 2015-11-27 | Spojina, postopek za njeno pripravo in njena uporaba |
PT158632174T PT3225627T (pt) | 2014-11-27 | 2015-11-27 | Composto tripeptídico, método de preparação para o mesmo e sua aplicação |
HUE15863217A HUE056645T2 (hu) | 2014-11-27 | 2015-11-27 | Tripeptidvegyület, elõállítási módszere, és alkalmazása |
IL252448A IL252448B (en) | 2014-11-27 | 2017-05-23 | A tripeptide compound, a method for its preparation and its application |
HK18102948.9A HK1243437A1 (zh) | 2014-11-27 | 2018-03-01 | 一類三肽化合物及其製備方法與應用 |
CY20211100983T CY1125043T1 (el) | 2014-11-27 | 2021-11-11 | Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410705180.3A CN105693817B (zh) | 2014-11-27 | 2014-11-27 | 一类三肽化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105693817A CN105693817A (zh) | 2016-06-22 |
CN105693817B true CN105693817B (zh) | 2020-06-05 |
Family
ID=56073634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410705180.3A Active CN105693817B (zh) | 2014-11-27 | 2014-11-27 | 一类三肽化合物及其制备方法与应用 |
Country Status (21)
Country | Link |
---|---|
US (1) | US11358985B2 (zh) |
EP (1) | EP3225627B9 (zh) |
JP (1) | JP6689848B2 (zh) |
KR (1) | KR102098783B1 (zh) |
CN (1) | CN105693817B (zh) |
AU (1) | AU2015353118B2 (zh) |
CA (1) | CA2968595C (zh) |
CY (1) | CY1125043T1 (zh) |
DK (1) | DK3225627T5 (zh) |
ES (1) | ES2897916T3 (zh) |
HK (1) | HK1243437A1 (zh) |
HU (1) | HUE056645T2 (zh) |
IL (1) | IL252448B (zh) |
MY (1) | MY193996A (zh) |
NZ (1) | NZ732301A (zh) |
PL (1) | PL3225627T3 (zh) |
PT (1) | PT3225627T (zh) |
RU (1) | RU2685709C2 (zh) |
SG (1) | SG11201704235SA (zh) |
SI (1) | SI3225627T1 (zh) |
WO (1) | WO2016082786A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107056788A (zh) * | 2017-03-23 | 2017-08-18 | 河南工程学院 | 一种咪唑烷酮类衍生物及其合成方法 |
CN107337712A (zh) * | 2017-07-26 | 2017-11-10 | 盐城卫生职业技术学院 | 一种抗高血压活性肽Orn‑Hyp‑Pro及应用和药物组合物 |
CN107337711A (zh) * | 2017-07-26 | 2017-11-10 | 盐城卫生职业技术学院 | 一种抗高血压活性肽Citn‑Pro‑Hyp及应用和药物组合物 |
CN112830884A (zh) * | 2019-11-22 | 2021-05-25 | 深圳市高盈医药科技开发有限公司 | 一种丹参素衍生物及其制备方法及其医药用途 |
US20240002359A1 (en) * | 2020-12-03 | 2024-01-04 | Merck Sharp & Dohme Llc | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1868998A (zh) * | 2006-05-15 | 2006-11-29 | 西北大学 | β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途 |
CN1939912A (zh) * | 2005-10-01 | 2007-04-04 | 代斌 | N-[2-(3-苯基-2-丙烯酰氨基)丙酰基]-噻唑烷酸及其衍生物制备方法 |
CN101607907A (zh) * | 2009-06-22 | 2009-12-23 | 西北大学 | 取代的苯甲酸衍生物及其合成方法和用途 |
CN104945469A (zh) * | 2015-06-30 | 2015-09-30 | 石狮海星食品有限公司 | Ace抑制三肽 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE252191C (zh) | ||||
IL60888A (en) | 1978-06-16 | 1984-07-31 | Yeda Res & Dev | Substrates and process for the quantitative assay of enzymes |
DE3315464A1 (de) | 1983-04-28 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern |
KR900008794B1 (ko) | 1986-06-11 | 1990-11-29 | 티 디 케이 가부시끼가이샤 | 방전 램프장치 |
DE3619633A1 (de) | 1986-06-11 | 1987-12-17 | Hoechst Ag | Peptide mit einfluss auf die diurese und natriurese, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
DE3839127A1 (de) * | 1988-11-19 | 1990-05-23 | Hoechst Ag | Pyrrolidon-2-carbonsaeure-derivate mit psychotroper wirkung |
DK0957903T3 (da) * | 1996-09-18 | 2005-11-21 | Applied Genetics Inc Dermatics | Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser |
WO2004024754A1 (ja) | 2002-09-11 | 2004-03-25 | Toaeiyo Ltd. | プロリンエステル類及びそれを含有する経皮投与製剤 |
GB2395195A (en) | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
PT1669463E (pt) | 2003-08-01 | 2009-01-23 | Calpis Co Ltd | Hidrolisado de caseína, processo para produção do mesmo e sua utilização |
BRPI1007600A2 (pt) | 2009-04-23 | 2019-09-24 | Invasc Therapeutics Inc | composições e métodos para tratamento de doenças cardiovasculares |
JP5799842B2 (ja) | 2012-02-03 | 2015-10-28 | 秋田県 | アンジオテンシン変換酵素阻害ペプチド、該ペプチドを含有するアンジオテンシン変換酵素阻害剤、組成物及び食品、並びに、該ペプチドの製造方法 |
CN102757479B (zh) | 2012-05-09 | 2014-04-30 | 北京林业大学 | 高活性降血压肽及其制备方法 |
JP2014141462A (ja) | 2012-12-27 | 2014-08-07 | Raffinee International Co Ltd | ペプチド、並びに、アンジオテンシン変換酵素阻害剤、抗高血圧剤、及び飲食品 |
-
2014
- 2014-11-27 CN CN201410705180.3A patent/CN105693817B/zh active Active
-
2015
- 2015-11-27 AU AU2015353118A patent/AU2015353118B2/en active Active
- 2015-11-27 CA CA2968595A patent/CA2968595C/en active Active
- 2015-11-27 PL PL15863217T patent/PL3225627T3/pl unknown
- 2015-11-27 KR KR1020177017351A patent/KR102098783B1/ko active IP Right Grant
- 2015-11-27 SI SI201531768T patent/SI3225627T1/sl unknown
- 2015-11-27 RU RU2017121590A patent/RU2685709C2/ru active
- 2015-11-27 MY MYPI2017701895A patent/MY193996A/en unknown
- 2015-11-27 EP EP15863217.4A patent/EP3225627B9/en active Active
- 2015-11-27 SG SG11201704235SA patent/SG11201704235SA/en unknown
- 2015-11-27 ES ES15863217T patent/ES2897916T3/es active Active
- 2015-11-27 HU HUE15863217A patent/HUE056645T2/hu unknown
- 2015-11-27 PT PT158632174T patent/PT3225627T/pt unknown
- 2015-11-27 JP JP2017527865A patent/JP6689848B2/ja active Active
- 2015-11-27 WO PCT/CN2015/095758 patent/WO2016082786A1/zh active Application Filing
- 2015-11-27 NZ NZ732301A patent/NZ732301A/en unknown
- 2015-11-27 US US15/529,633 patent/US11358985B2/en active Active
- 2015-11-27 DK DK15863217.4T patent/DK3225627T5/da active
-
2017
- 2017-05-23 IL IL252448A patent/IL252448B/en active IP Right Grant
-
2018
- 2018-03-01 HK HK18102948.9A patent/HK1243437A1/zh unknown
-
2021
- 2021-11-11 CY CY20211100983T patent/CY1125043T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939912A (zh) * | 2005-10-01 | 2007-04-04 | 代斌 | N-[2-(3-苯基-2-丙烯酰氨基)丙酰基]-噻唑烷酸及其衍生物制备方法 |
CN1868998A (zh) * | 2006-05-15 | 2006-11-29 | 西北大学 | β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途 |
CN101607907A (zh) * | 2009-06-22 | 2009-12-23 | 西北大学 | 取代的苯甲酸衍生物及其合成方法和用途 |
CN104945469A (zh) * | 2015-06-30 | 2015-09-30 | 石狮海星食品有限公司 | Ace抑制三肽 |
Non-Patent Citations (4)
Title |
---|
Improved Process for Pilot-Scale Synthesis of Danshensu ((±)-DSS) and Its Enantiomer Derivatives;Yajun Bai et al.;《Organic Process Research & Development》;20131126;第18卷;第1667-1673页 * |
Preparation of L-proline based aeruginosin 298-A analogs: Optimization of the P1-moiety;G Wang et al.;《Bioorganic & Medicinal Chemistry Letters》;20090419;第19卷(第14期);第3798-3803页 * |
Total Synthesis and Biological Evaluation of Grassypeptolide A;Hui Liu et al.;《Chem. Eur. J.》;20131231;第19卷;第6774-6784页 * |
基于君臣佐使配伍理论的药物分子设计、合成与活性研究;白亚军;《中国博士学位论文全文数据库 医药卫生科技辑》;20160115(第1期);第E057-18页 * |
Also Published As
Publication number | Publication date |
---|---|
RU2017121590A (ru) | 2018-12-27 |
EP3225627A1 (en) | 2017-10-04 |
NZ732301A (en) | 2018-05-25 |
RU2685709C2 (ru) | 2019-04-23 |
JP2018505847A (ja) | 2018-03-01 |
AU2015353118B2 (en) | 2018-12-13 |
PL3225627T3 (pl) | 2022-02-28 |
IL252448B (en) | 2019-09-26 |
WO2016082786A1 (zh) | 2016-06-02 |
KR20170087497A (ko) | 2017-07-28 |
US20170267718A1 (en) | 2017-09-21 |
RU2017121590A3 (zh) | 2018-12-27 |
EP3225627A4 (en) | 2018-08-22 |
ES2897916T3 (es) | 2022-03-03 |
KR102098783B1 (ko) | 2020-04-10 |
SG11201704235SA (en) | 2017-06-29 |
PT3225627T (pt) | 2021-11-17 |
US11358985B2 (en) | 2022-06-14 |
CY1125043T1 (el) | 2023-06-09 |
IL252448A0 (en) | 2017-07-31 |
DK3225627T3 (zh) | 2021-11-29 |
CN105693817A (zh) | 2016-06-22 |
JP6689848B2 (ja) | 2020-04-28 |
CA2968595C (en) | 2019-09-24 |
CA2968595A1 (en) | 2016-06-02 |
SI3225627T1 (sl) | 2022-02-28 |
EP3225627B9 (en) | 2022-01-05 |
HK1243437A1 (zh) | 2018-07-13 |
MY193996A (en) | 2022-11-07 |
EP3225627B1 (en) | 2021-11-03 |
DK3225627T5 (da) | 2022-02-28 |
HUE056645T2 (hu) | 2022-02-28 |
AU2015353118A1 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105693817B (zh) | 一类三肽化合物及其制备方法与应用 | |
JP6830671B6 (ja) | γ−ヒドロキシ酪酸(GHB)のプロドラッグ、その組成物および使用 | |
JP4691549B2 (ja) | Iapの阻害剤 | |
EP3313388A1 (en) | Chemical modulators of signaling pathways and therapeutic use | |
US11203597B2 (en) | Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing | |
EP1679309A1 (en) | Antistress drug and medical use thereof | |
CN114057702B (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
RU2557235C1 (ru) | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты | |
CN112592331B (zh) | 一种奥司他韦protac化合物及其制备方法与在抗流感病毒药物中的应用 | |
WO1995003277A1 (fr) | Nouveau derive de pyrrolidine | |
CN115960088A (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
KR20230048373A (ko) | 저분자량 단백질 분해제 및 이의 응용 | |
Omar et al. | Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma | |
AU2014311221B2 (en) | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | |
WO1998046569A1 (fr) | Derives de benzene | |
CN113461563A (zh) | Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用 | |
US20070082922A1 (en) | Huperzine a prodrugs and uses thereof | |
CN113620887B (zh) | 一类sirt5蛋白抑制剂及其用途 | |
KR101497979B1 (ko) | 인돌 유도체 및 이를 포함하는 rage 관련 질환의 예방 또는 치료용 약학적 조성물 | |
CN116354892A (zh) | 一类sirt5蛋白抑制剂及其用途 | |
OA18217A (en) | Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer. | |
JP2007169188A (ja) | 新規安息香酸ベンジル誘導体及び医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |